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This analysis assessed the effect of lenalidomide on progres-
sion-free survival (PFS). Patients with relapsed or refractory
multiple myeloma (RRMM) who received lenalidomide plus
dexamethasone in the MM-009 and MM-010 trials were pooled
and those who had not progressed and were still receiving
lenalidomide at 12 months were included. The median follow-up
of surviving patients was 48 months. Of 353 patients who
received lenalidomide plus dexamethasone, 116 (33%) had not
progressed. Overall, 52 patients (45%) had no dose reductions,
25 (22%) had dose reductions X12 months and 39 (34%) had
dose reductions before 12 months. Patients who had dose
reductions X12 months had a signiﬁcantly longer median PFS
than those who had reductions before 12 months (P¼0.007) or
no dose reductions (P¼0.039) (not reached vs 28.0 vs 36.8
months, respectively). In a multivariate Cox regression model,
dose reduction X12 months was an independent predictor of
improved PFS (hazard ratio, 0.47; 95% conﬁdence interval,
0.23–0.98) after adjusting for patient characteristics. The data
suggest that to achieve maximum PFS beneﬁt, patients with
RRMM should be treated for X12 months with full-dose
lenalidomide plus dexamethasone. Thereafter, patients may
beneﬁt from lower-dose continued therapy; prospective studies
are needed to conﬁrm these ﬁndings.
Leukemia (2011) 25, 1620–1626; doi:10.1038/leu.2011.126;
published online 12 July 2011
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Introduction
Despite recent improvements in survival outcomes,
1,2 multiple
myeloma (MM) remains an incurable disease associated with
uncontrolled plasma cell growth, immunodeﬁciency and high
rates of relapse. Lenalidomide is an oral ImiDs
s immunomo-
dulatory compound with a dual mechanism of action. It has a
tumoricidal effect that leads directly to tumor cell death and an
immunomodulatory effect that keeps the tumor in remission.
3
The combination of these effects provides both immediate and
sustained myeloma control when lenalidomide is used long
term. Currently, lenalidomide is indicated in combination with
dexamethasone for the treatment of patients with relapsed or
refractory (RR) MM who have received at least one previous
therapy. Approval was based primarily on the results of two
pivotal, phase III, randomized, double-blind, placebo-controlled
trials conducted mainly in North America (MM-009)
4 and
Europe (MM-010).
5 Compared with dexamethasone alone,
lenalidomide plus dexamethasone signiﬁcantly prolonged time
to progression and overall survival, and had an acceptable safety
proﬁle.
4–6
Exploratory sub-analyses of data from the MM-009 and MM-
010 trials indicate that response rates appear to improve with
continued treatment with lenalidomide plus dexamethasone,
7
and that continued treatment after achievement of best response
is associated with prolonged survival compared with earlier
discontinuation.
8 These ﬁndings demonstrate that continuing
lenalidomide-based therapy is essential for maximum therapeu-
tic beneﬁt, although the optimal dose and schedule of long-term
lenalidomide-based continuous therapy in this setting is
unknown. Furthermore, certain adverse events associated with
lenalidomide, such as neutropenia and thrombocytopenia, often
warrant dose reductions or delays, which may hinder the
delivery of long-term therapy. We therefore performed an
exploratory analysis using data from the MM-009 and MM-010
trials to determine whether reducing the dose of lenalidomide
and the timing of the dose reduction inﬂuences progression-free
survival (PFS).
Patients and methods
Data from patients who received lenalidomide plus dexametha-
sone in the MM-009 (up to 23 July 2008) and MM-010 (up to
2 March 2008) trials were included in this analysis. These trials
were approved by the relevant institutional review boards and
ethics committees, and all patients gave written informed
consent. To control for selection bias, only patients who had
not progressed and were still receiving lenalidomide at 12
months were included. These patients were categorized as
having dose reductions or no dose reductions, and those
requiring dose reductions were further classiﬁed as having dose
reductions after X12 months or within 12 months of starting
therapy. The median follow-up of surviving patients included in
this analysis was 48 months.
All patients began lenalidomide therapy at 25mg/day for 21
days of each 28-day cycle. All patients received the same initial
dose of oral dexamethasone (40mg on days 1–4, 9–12 and
17–20 of each 28-day cycle; after the fourth cycle, dexametha-
sone was administered on days 1–4 only). As previously
described,
4,5 protocol-sanctioned dose reductions of lenalido-
mide and dexamethasone were allowed for adverse events.
A series of landmark analyses were performed, including only
patients still on study at 6, 9 and 12 months in order to
determine the impact of lenalidomide dose reductions on PFS at
the different time points. PFS was evaluated using Kaplan–Meier
analyses, and the log-rank test was used for comparing the
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www.nature.com/leugroups. At 6 and 9 months, median PFS for patients with a dose
reduction after the speciﬁed time was better than for the other
two groups, but not signiﬁcantly so. However, at 12 months,
there was a statistically signiﬁcant difference in PFS between
groups. Therefore, 12 months was used in this study.
Patient characteristics and laboratory values at baseline and
12 months were included in a univariate Cox regression analysis
of PFS. Dose reduction (‘o12 months’, ‘X12 months’ or ‘no
dose reduction’) was coded as two dummy variables. All
covariates with Po0.25 in the univariate analysis were included
in a multivariate analysis. All possible regression models were
run and the ‘best’ subset of covariates was selected. To identify
baseline covariates that predicted dose reduction after X12
months, a logistic regression analysis was performed using ‘dose
reduction X12 months’ as the dependent variable.
Results
A total of 353 patients received lenalidomide plus dexametha-
sone in the MM-009 (N¼177) and MM-010 (N¼176) trials. Of
these, 116 (32.9%) had not progressed and were still receiving
study treatment at 12 months and, therefore, were included in
the current analysis (60 patients from MM-009 and 56 patients
from MM-010). The remaining 237 patients had documented
disease progression or discontinued study treatment within the
ﬁrst 12 months of therapy. Of the 116 evaluable patients, 52
patients (45%) had no dose reductions, 39 patients (34%) had
lenalidomide dose reductions before 12 months and 25 patients
(22%) had lenalidomide dose reductions after X12 months.
Patient disposition is summarized in Figure 1.
Patient demographics and clinical characteristics are shown
in Table 1. Baseline characteristics were comparable between
the three groups; however, among patients with early or late
dose reduction, a higher proportion had an Eastern Cooperative
Oncology Group (ECOG) performance status score of X1 (56%
and 76%, respectively), compared with patients who had no
dose reduction (38%). In addition, the burden of disease
(measured by a b2-microglobulin level of X2.5mg/l) was higher
in patients with dose reductions before 12 months (77%)
compared with patients who had dose reductions after X12
months (60%) or no dose reduction (48%).
Response and outcomes
Response rates were similarly high in all three patient
subgroups: a partial response or better was achieved in all
patients with a dose reduction and 49 of the 52 patients (94%)
without a dose reduction. The rate of complete response was
higher in patients with dose reductions after X12 months (52%),
compared with those with early (31%) or no (40%) dose
reductions. Median PFS for each patient subgroup is shown in
Table 2 and Figure 2. Patients who had dose reductions after
X12 months had signiﬁcantly longer PFS (not reached (NR))
than those who had dose reductions before 12 months of starting
therapy (28.0 months, P¼0.007) and those without dose
reductions (36.8 months, P¼0.039) (Table 2). Median overall
survival was NR in any of the three subgroups. Consistent with
the PFS ﬁndings, median overall survival was signiﬁcantly
longer in patients who had dose reductions after X12 months
(NR; 95% conﬁdence interval (CI), NR–NR) compared with
those who had dose reductions before 12 months (NR; 95% CI,
38.5–NR; P¼0.022) and those who had no dose reductions
(NR; 95% CI, 47.1–NR; P¼0.103).
Predictors of PFS in Cox regression analysis
Covariates considered for analysis are shown in Supplementary
Table S1. Univariate analysis indicated that dose reductions
after X12 months were associated with longer PFS compared
Patients who received Len+Dex 
in the MM-009 and MM-010 trials
N = 353
Not progressed*
N = 116
Progressed or discontinued 
treatment
n = 237
No dose reduction 
n = 52
Dose reduction 
< 12 months
n = 39
Dose reduction 
≥12 months
n = 25
Figure 1 Flow diagram demonstrating the disposition and lenalido-
mide dose reductions of 353 patients included in the study. LenþDex,
lenalidomide plus dexamethasone. *Patients still receiving lenalido-
mide at 12 months.
Table 1 Demographic and clinical characteristics
Dose reduction
X12 Months
(n¼25)
o12 Months
(n¼39)
No dose
reduction
(n¼52)
Age, years
Median 64 65 59.5
Range 45–81 46–81 33–81
Sex, n (%)
Male 15 (60.0) 24 (61.5) 29 (55.8)
Female 10 (40.0) 15 (38.5) 23 (44.2)
Time since diagnosis, years
Median 3.4 3.2 2.9
Range 0.4–10.4 0.8–14.6 0.5–13.6
Durie–Salmon stage, n (%)
I 3 (12.0) 2 (5.1) 2 (3.8)
II 9 (36.0) 12 (30.8) 16 (30.8)
III 13 (52.0) 25 (64.1) 34 (65.4)
ECOG performance status, n (%)
0 5 (20.0) 15 (38.5) 29 (55.8)
1 13 (52.0) 16 (41.0) 19 (36.5)
2 6 (24.0) 6 (15.4) 1 (1.9)
Missing 1 (4.0) 2 (5.1) 3 (5.8)
Previous therapy, n (%)
1 previous therapy 10 (40.0) 15 (38.5) 20 (38.5)
X2 previous therapies 12 (48.0) 22 (56.4) 25 (48.1)
Type of therapy, n (%)
Thalidomide 7 (28.0) 16 (41.0) 14 (26.9)
Bortezomib 2 (8.0) 5 (12.8) 3 (5.8)
Stem-cell
transplantation
12 (48.0) 21 (53.8) 32 (61.5)
b2-Microglobulin level, n (%)
o2.5mg/l 10 (40.0) 9 (23.1) 27 (51.9)
X2.5mg/l 15 (60.0) 30 (76.9) 25 (48.1)
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
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Leukemiawith the other two subgroups, and dose reductions before 12
months of starting therapy were associated with shorter PFS
compared with the other two subgroups. Other relevant factors
identiﬁed in the univariate analysis are listed in Table 3. In a
multivariate analysis, lenalidomide dose reductions after X12
months remained an independent predictor of PFS (hazard ratio,
0.47; 95% CI, 0.23–0.98). Other independent predictors of PFS
were serum albumin, the percentage of neutrophils and
M-protein, all at 12 months (Table 3).
Proportion of dose received and days treated
As expected, the proportion of full-dose lenalidomide received
(25mg/day for 21 days of each 28-day cycle) was lower in the
groups that required dose reductions, compared with those who
did not require dose reductions (Table 4). Nevertheless, the
proportion of days treated was similar among the three
subgroups, indicating that patients in all three subgroups
required dose interruptions at some point during treatment.
The median dose of dexamethasone was similar in all three
subgroups; however, differences in the proportion of the target
dexamethasone dose received were noted between the groups,
especially after the second year of treatment (Table 4). Both
subgroups of patients with dose reductions received 46–56% of
the target dexamethasone dose during the third and fourth years
of treatment, compared with 86–88% for patients with no dose
reductions.
Neutropenia and thrombocytopenia
As expected, neutropenia and thrombocytopenia were more
common in patients who had dose reductions than in those who
had no dose reductions (Table 5). Among those who required
dose reductions, the incidence of grade 3 or 4 neutropenia was
64% in those who had dose reductions after X12 months and
67% in those who had dose reductions before 12 months of
starting therapy; the incidence was 39% in those with no dose
reductions (Table 5). Of note, the incidence of thrombocytope-
nia was higher in patients who had dose reductions before 12
months of therapy (31%), compared with those who had dose
reductions after X12 months or no dose reductions (8% and
6%, respectively). The proportion of patients without any grade
X3 events of neutropenia or thrombocytopenia was greater in
the group that had no dose reductions (58%) than in those with
dose reductions (36% and 23% for those with late and early
dose reductions, respectively). Among patients who developed
grade 3 or 4 neutropenia, 44–50% received granulocyte colony-
stimulating factor in each dose reduction group (Table 5).
Notably, granulocyte colony-stimulating factor was more read-
ily administered for neutropenia in patients who had no dose
reductions (59% of events), than in patients who had dose
reductions before 12 months (42% of events) or dose reductions
after X12 months (28% of events) (data not shown). Neutropenia
or infection was the cause for dose reductions in 18 of 25
patients (72%) who had dose reductions after X12 months. The
remaining seven patients had dose reductions for other adverse
events, including asthenia, edema and neuropathy.
Predictor of dose reductions after 12 months in logistic
regression analysis: performance status
Logistic regression identiﬁed ECOG score at baseline (X1v s0 )
as the strongest predictor of dose reductions after X12 months
(odds ratio, 0.25; 95% CI, 0.09–0.73). Of the 110 evaluable
patients with ECOG scores available, 61 patients (56%) had an
ECOG score of X1. Overall, 79% of patients who had
lenalidomide dose reductions after X12 months, 59% of
patients with dose reductions before 12 months and 41% of
patients with no dose reductions had ECOG scores of X1.
Table 2 Landmark analyses performed at 6, 9 and 12 months to determine the impact of lenalidomide dose on PFS
Median PFS, months (95% CI)
Dose reduction at or after time point Dose reduction before time point No dose reduction
6 months n¼50 n¼40 n¼79
28.6 (20.5–46.9) 24.7 (16.6–36.7) 19.8 (25.1–29.0)
P¼0.388 P¼0.069
9 months n¼39 n¼37 n¼63
44.4 (21.9–NR) 24.7 (17.0–36.7) 26.2 (19.7–39.6)
P¼0.256 P¼0.128
12 months n¼25 n¼39 n¼52
NR (35.7–NR) 28.0 (17.5–36.7) 36.8 (22.1–NR)
P¼0.007 P¼0.039
Abbreviations: CI, conﬁdence interval; NR, not reached; PFS, progression-free survival.
P-values are vs dose reduction after time point (log-rank test).
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Figure 2 PFS (months) of MM patients according to lenalidomide
dose reduction group, o12 months (n¼39), X12 months (n¼25) or
no dose reduction (n¼52). Median PFS was signiﬁcantly longer in
patients who had dose reductions X12 months as compared with
those who had dose reductions o12 months (P¼0.007) and those
without dose reductions (P¼0.039).
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LeukemiaPatients with an ECOG score of X1 were three times more likely
to have a dose reduction after X12 months than those who had
an ECOG score of 0 (31 vs 10%; Po0.01).
Discussion
This subanalysis of data from the MM-009 and MM-010 trials
showed that, among patients who required lenalidomide dose
reductions, those who had dose reductions after X12 months of
full-dose lenalidomide (25mg/day for 21 days of each 28-day
cycle) had a signiﬁcantly higher median PFS and overall survival
than those who had earlier dose reductions. These data
underscore the importance of continuing full-dose lenalidomide
therapy for at least 12 months in patients who are able to
tolerate the treatment. Patients who had dose reductions after
X12 months also had a signiﬁcantly higher median PFS than
those who had never had dose reductions. Therefore, the
Table 3 Cox regression analysis of PFS
Covariate HR (95% CI)
Univariate model
a (n¼116) Multivariate model (n¼101)
Dose reduced after X12 months (yes vs no) 0.42 (0.21–0.86)
b 0.47 (0.23–0.98)
Dose reduced before 12 months (yes vs no) 1.73 (1.03–2.91)
b
Age, years 1.02 (1.00–1.05)
ISS disease stage at baseline (stage 1, 2, 3) 1.45 (0.92–2.28)
Bone marrow cellularity, % 1.01 (1.00–1.02)
Bone marrow cellularity (o33% vs X33%) 1.43 (0.86–2.36)
Serum albumin at 12 months, g/dl 0.53 (0.25–1.26) 0.29 (0.11–0.75)
Calcium at baseline (p10% vs 410%) 0.56 (0.30–1.07)
Calcium at 12 months (p10% vs 410%) 2.38 (0.73–7.73)
Neutrophils at 12 months, % 1.02 (1.00–1.04) 1.02 (1.00–1.04)
Neutrophils (absolute) at 12 months,  10
3/l 1.06 (0.84–1.34)
M-protein at 12 months, g/l 1.07 (1.00–1.14)
b 1.07 (1.00–1.14)
ECOG score at baseline (X1 vs 0) 1.00 (0.60–1.67)
Chi-square(df) Chi-square(4)¼16.60
P¼0.003
AIC¼423.56
Abbreviations: AIC, Akaike’s information criterion; CI, conﬁdence interval; df, degrees of freedom; ECOG, Eastern Cooperative Oncology Group;
HR, hazard ratio; ISS, International Staging System.
aAll listed univariate covariates had a P-value of o0.25 and were considered in the multivariate analysis.
bPo0.05 for the univariate model.
Table 4 Proportion of full-dose lenalidomide received, days treated and median dexamethasone dose, according to dose reduction
Dose reduction
X12 Months
(n¼25)
o12 Months
(n¼39)
No dose reduction
(n¼52)
Median proportion of lenalidomide dose received, % (25%, 75%)
a 72.2 (63.4, 84.0) 50.5 (34.5, 63.8) 90.4 (83.5, 98.4)
Median proportion of days treated, % (25%, 75%)
b 88.7 (79.2, 96.4) 89.1 (82.2, 93.6) 90.4 (83.5, 98.4)
Median dexamethasone dose, mg (25%, 75%)
c 40.0 (30.3, 40.0) 40.0 (37.2, 40.0) 36.3 (29.4, 40.0)
Proportion of dexamethasone dose received, %
d
Year 1 (target 9.2mg/day) 87 (n¼25) 88 (n¼39) 96 (n¼52)
Year 2 (target 5.7mg/day) 109 (n¼25) 114 (n¼39) 91 (n¼52)
Year 3 (target 5.7mg/day) 56 (n¼22) 49 (n¼19) 86 (n¼33)
Year 4 (target 5.7mg/day) 53 (n¼15) 46 (n¼11) 88 (n¼23)
aTotal target dose was 25mg/day.
bTotal target days of treatment was 21 days per 28-day cycle.
cReﬂects dose on days of treatment. Per protocol patients received 40mg/day dexamethasone for days 1–4, 9–12 and 17–20 for four cycles, and
then 40mg/day for days 1–4 for subsequent cycles.
dMedian target dose is calculated as total dose received/days on study.
Table 5 Incidence of grade 3 or 4 neutropenia, febrile neutropenia
and thrombocytopenia
Grade 3 or 4 event, n (%) Dose reduction
X12 Months
(n¼25)
o12 Months
(n¼39)
No dose
reduction
(n¼52)
Neutropenia
a 16 (64) 26 (67) 20 (39)
G-CSF 7 (44) 12 (46) 10 (50)
No G-CSF 9 (56) 14 (54) 10 (50)
Febrile neutropenia
b 1 (4) 3 (8) 1 (2)
Thrombocytopenia 2 (8) 12 (31) 3 (6)
No events 9 (36) 9 (23) 30 (58)
Abbreviation: G-CSF, granulocyte colony-stimulating factor.
aNeutropenia included the terms ‘neutropenia’, ‘febrile neutropenia’
and ‘neutrophil count decreased’.
bFebrile neutropenia included the terms ‘febrile neutropenia’ and
‘neutropenic sepsis’.
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for X12 months before dose reductions cannot be attributed to a
selection bias of generally healthier patients. In fact, this group
had the highest proportion of patients with an ECOG score of
X1, which is associated with a worse prognosis. Furthermore,
the relationship between dose reductions after X12 months and
PFS was independent of other factors measuring disease
severity, such as b2-microglobulin or International Staging
System disease stage, as found in the Cox regression analysis.
Of note, it is unlikely that the imbalance between the groups in
b2-microglobulin levels confounded the results because there
was no association between b2-microglobulin levels and PFS in
the univariate analysis.
As expected, neutropenia and thrombocytopenia were more
frequently observed in patients who had dose reductions.
Careful monitoring and management of myelosuppression with
growth factors during the ﬁrst 12 months of treatment may help
to avoid severe cases of neutropenia or thrombocytopenia,
which necessitate early dose reductions or interruptions. The
inferior PFS observed in patients who had dose reductions
within 12 months of starting therapy underscores the importance
of adverse-event management and delivering full doses of
lenalidomide therapy for X12 months. The present data also
suggest that after 12 months, the lenalidomide dose can be
reduced for adverse events without compromising efﬁcacy.
This analysis has several limitations. It is exploratory in nature
and is based on a small number of patients in each subgroup.
After adjusting for all measured covariates at baseline and at 12
months, patients with dose reductions after X12 months still
had signiﬁcantly longer PFS. However, because decisions to
reduce the dose were based on investigators’ assessment of
individual clinical status, and not as deﬁned by the protocol, it is
possible that there are patient clinical parameters not included
in this analysis that could potentially explain the longer PFS
among patients with dose reductions after X12 months.
This analysis of pooled data from the MM-009 and MM-010
trials is consistent with evidence that continued therapy with
lenalidomide plus dexamethasone is associated with clinical
beneﬁt. Harousseau et al.
7 reported that half of the patients
initially classiﬁed as having a partial response to lenalidomide
plus dexamethasone eventually had a complete response or
near-complete response after receiving additional cycles of
therapy. In the present analysis, the rate of complete response
was higher in patients with dose reductions after X12 months
(52%) than in patients with dose reductions before 12 months
(31%) or no dose reductions (40%), suggesting deepening
responses with continued treatment. San Miguel et al.
8 demon-
strated that continuing treatment after achievement of best
response signiﬁcantly prolonged survival compared with earlier
discontinuation. Together, these ﬁndings conﬁrm the impor-
tance of continuing treatment with lenalidomide plus dexa-
methasone in patients with RRMM.
The cellular effects of lenalidomide suggest that chronic use
may be beneﬁcial.
9 Lenalidomide exerts both direct tumoricidal
effects that lead to tumor cell death and immunomodulatory
effects that may help to keep tumors in remission. These occur
via the direct inhibition of myeloma cell growth and induction
of apoptosis;
10–12 immunomodulation, including inhibition of
myeloid cells and co-stimulation of lymphoid cells;
13–17 and
inhibition of angiogenesis.
18–21 Lenalidomide also modulates
several cytokines, including inhibition of myeloid cell produc-
tion of tumor necrosis factor-a, a growth and survival factor for
MM cells.
13,22 Moreover, lenalidomide also stimulates T cells as
well as natural killer cells, which may help to develop innate
anticancer immunity.
15–17,23,24
It has been suggested that, although the tumoricidal effects of
lenalidomide in combination with dexamethasone may be
responsible for the initial response to therapy, the immunomo-
dulatory effects of lenalidomide may have an important role in
maintaining long-term disease control.
12 On the basis of in vitro
pharmacology, the immunomodulatory effects of lenalidomide
are more potent than its direct tumoricidal effects, and therefore
these effects may be predominant at lower doses. The maximum
plasma concentration for lenalidomide following a 25mg dose
in patients with normal renal function is 2.19mM (568ng/ml).
25
Proliferation of 4 of 10 myeloma cell lines is inhibited by
lenalidomide with a half maximal inhibitory concentration
(IC50)o fp2.1mM.
12 In comparison, lenalidomide shows
immunomodulatory properties at concentrations of o40nM
(o10.4ng/ml), reaching maximal enhancement at 1mM
(259ng/ml).
12 The present ﬁndings combined with these
in vitro observations suggest that, following at least 12 months
of treatment, lenalidomide’s immunomodulatory properties,
exerted even at lower doses, may be sufﬁcient for adequate
control of the residual tumor in RRMM. Further studies are
needed to conﬁrm this hypothesis.
Although lenalidomide acts synergistically with dexametha-
sone to inhibit myeloma cell proliferation in vitro, its
immunomodulatory activity is antagonized by dexametha-
sone.
12,26,27 In this analysis, the median dexamethasone dose
was comparable in all three subgroups (40, 40 and 36.3mg in
the X12 months, o12 months or no reduction groups,
respectively). This reﬂects actual dose received on days in
which there was no dose interruption divided by the number of
actual treatment days. After 2 years of treatment, patients with
lenalidomide dose reductions (X12 months and o12 months)
also received a lower proportion of the target dexamethasone
dose compared with those without lenalidomide dose reduc-
tions. The enhanced efﬁcacy and improved tolerability achieved
when administering full-dose lenalidomide with reduced-dose
dexamethasone, deﬁned as p20mg/day for just 4 days during
the ﬁrst 4 cycles or p20mg/day in subsequent cycles, was
demonstrated by San Miguel et al.
28 in another subset analysis
from MM-009 and MM-010 trials. In a recent ECOG study
(E4A03) conducted in patients with newly diagnosed MM, a
regimen of lenalidomide plus low-dose dexamethasone was
more clinically effective than the standard regimen.
29 One
explanation for the results is the improved tolerability of the
low-dose dexamethasone regimen, which resulted in lower
incidence of serious adverse events, including thromboembo-
lism.
29 Another explanation could be that lower doses of the
immunosuppressant dexamethasone led to less antagonism of
the immunomodulatory effects of lenalidomide, which in turn
resulted in better disease control, as discussed above.
12,26,27
This is supported by a number of studies that investigated
steroid-sparing approaches and that demonstrated the efﬁcacy
and tolerability of single-agent lenalidomide in patients with
MM.
30–32 Furthermore, emerging lenalidomide maintenance
phase III studies in the frontline setting suggest that maintenance
therapy with single-agent lenalidomide (10–15mg/day, for 21 of
28 days or continuously) signiﬁcantly prolongs PFS and duration
of response, reducing the risk of disease progression by up to
61%.
33–35 In the absence of maintenance studies in the relapsed
setting, consensus guidelines for treatment of patients with
RRMM recommend long-term continued treatment with lenali-
domide plus dexamethasone with dose modiﬁcations for
adverse events for both agents if required.
36
Recently, cases of second primary malignancies (SPMs) have
been observed in newly diagnosed patients with myeloma
treated with lenalidomide maintenance after high-dose
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MM-010 data, the incidence rates of SPM were assessed in
comparison with background cancer rates based on cancer
registry data (SEER database) to better characterize the
signiﬁcance of these observations.
37,38 The incidence of SPMs
was low during double-blind treatment and no acute myeloid
leukemia or B-cell malignancies were observed. Importantly,
the observed incidence rates of solid-tumor SPMs were not
different from the incidence rates observed in the general
population.
38 Considering a survival beneﬁt was observed
during long-term follow-up of the MM-009 and MM-010 trials,
despite a signiﬁcant number of patients in the placebo and
dexamethasone arm crossing over to receive lenalidomide-
based therapy, the low number and type of SPMs observed did
not change the beneﬁt–risk proﬁle for lenalidomide in RRMM
patients.
38
In this study, PFS beneﬁt was seen in patients with
lenalidomide dose reductions after X12 months; and a
reduction in dexamethasone dose was observed after the second
year. Altogether, the present ﬁndings can be explained by the
mechanism of action of lenalidomide; full-dose lenalidomide in
combination with dexamethasone seems to be directly tumor-
icidal whereas lenalidomide, even at reduced doses, in
combination with lower-dose dexamethasone may provide
immunomodulatory effects.
A better understanding of the immune effects of lenalidomide
in the patient may help to determine an appropriate dose and
schedule for optimal biologic effect during maintenance
therapy. Additional studies on the immunomodulatory proper-
ties of continuous lenalidomide therapy are in progress.
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